Pathways of purine metabolism in human adipocytes. Further evidence against a role of adenosine as an endogenous regulator of human fat cell function.
Previous results demonstrated that the adenosine that accumulates in human fat cell suspensions is derived from extracellular sources (Kather, H. (1988) J. Biol. Chem. 263, 8803-8809). To get insight into the mechanisms responsible for the lack of adenosine release, extracellular adenine nucleotide catabolism was minimized by 10 mmol/liter beta-glycerophosphate and 10 mumol/liter alpha,beta-methyleneadenosine 5'-diphosphate. Intracellular adenine nucleotide catabolism resulted in a release of inosine and hypoxanthine under these conditions that was increased markedly by isoproterenol. Experiments with inhibitors of adenosine deaminase and adenosine kinase indicated that the production of inosine and hypoxanthine proceeded via AMP deamination. Consistently, IMP levels were increased transiently in the presence of isoproterenol. In addition, the cells possessed a nucleotide phosphomonoesterase that was resistant to the inhibitory actions of ATP and alpha,beta-methyleneadenosine 5'-diphosphate and showed preference for IMP over AMP. Adenosine (approximately 1 nmol/10(6) cells/h) was also produced inside the cells. However, adenosine production was unrelated to ATP turnover via adenylate cyclase, and any adenosine formed was immediately reconverted to adenine nucleotides in the absence and presence of isoproterenol. It was concluded that adenosine is not released by intact human adipocytes, because the alternative routes of intracellular AMP catabolism are compartmentalized (at least in functional terms), and adenosine kinase is not saturated with substrate in the absence and presence of isoproterenol.
Kather
H
H
Klinisches Institut für Herzinfarktforschung, Medizinischen Universitätsklinik Heidelberg, West Germany.
D000241:Adenosine / Q000502:physiology*; D058892:Adenosine Deaminase Inhibitors; D000244:Adenosine Diphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D005994:Glycerophosphates / Q000494:pharmacology; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000378:metabolism; D007288:Inosine / Q000378:metabolism; D007291:Inosine Monophosphate / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008066:Lipolysis / Q000187:drug effects; D015649:Pentostatin / Q000494:pharmacology; D011687:Purines / Q000378:metabolism*; D014372:Tubercidin / Q000031:analogs & derivatives / Q000494:pharmacology
C040541:5'-deoxy-5-iodotubercidin; D058892:Adenosine Deaminase Inhibitors; D005994:Glycerophosphates; D007042:Hypoxanthines; D011687:Purines; C523965:alpha,beta-methyleneadenosine 5'-diphosphate; D007291:Inosine Monophosphate; D019271:Hypoxanthine; D015649:Pentostatin; D000249:Adenosine Monophosphate; D007288:Inosine; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000248:Adenosine Kinase; D000241:Adenosine; D007545:Isoproterenol; D014372:Tubercidin; C031463:beta-glycerophosphoric acid